Future directions in the treatment of pancreatic cancer

Seminars in Oncology

Volumn 29, Issue 6 SUPPL. 20, 2002, Pages 31-39

  Haller, Daniel G ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; DOCETAXEL; FLUOROURACIL; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PEMETREXED; TIPIFARNIB; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CLINICAL STUDY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GASTROINTESTINAL TUMOR; HUMAN; MAJOR CLINICAL STUDY; PANCREAS CARCINOMA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STANDARD; UNITED STATES;

EID: 0036991860     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.37381     Document Type: Conference Paper

References (23)

1. Evans DB, Abbruzzese JL, Rich TA: Cancer of the pancreas, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (4th ed). Philadelphia, PA, Lippincott, 1997, pp 1054-1087
2. Karpoff HM, Klimstra DS, Brennan MF, et al: Results of total pancreatectomy for adenocarcinoma of the pancreas. Arch Surg 136:44-47, 2001
3. Foo ML, Gunderson LL, Nagorney DM, et al: Patterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation +/- 5 fluorouracil. Int J Radiat Oncol Biol Phys 26:483-489, 1993
4. Moertel CG, Frytak S, Hahn RG, et al: Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 48:1705-1710, 1981
5. Kalser MH, Ellenberg SS: Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 120:899-903, 1985
6. Gastrointestinal Tumor Study Group: Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 59:2006-2010, 1987
7. Klinkenbijl JH, Jeekel J, Sahmoud T, et al: Adjuvant radiotherapy and 5-flourouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann Surg 230:776-784, 1999
8. Spitz FR, Abbruzzese JL, Lee JE, et al: Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 15:928-937, 1997
9. Glimelius B: Chemotherapy in the treatment of cancer of the pancreas. J Hepatobiliary Pancreat Surg 5:235-241, 1998
10. Burris HA III, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15:2403-2413, 1997
11. Tempero M, Plunkett W, Ruiz van Harperen V, et al: Randomized phase II trial of dose intense gemcitabine by standard infusion vs. fixed dose rate in metastatic pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 18:A1048, 1999 (abstr)
12. Berlin JD, Catalano P, Thomas JP, et al: Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20:3270-3275, 2002
13. Stathopoulos G, Rigatos G, Dimopoulos M, et al: Frontline treatment of pancreatic carcinoma with gemcitabine (GMB) in combination with irinotecan (CPT-11): Preliminary results of a multicenter phase II study. Proc Am Soc Clin Oncol 19:A1260, 2000 (abstr)
14. Rocha Lima CM, Savarese D, Bruckner H, et al: Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol 20:1182-1191, 2002
15. Heinemann V: Present and future treatment of pancreatic cancer. Semin Oncol 29:23-31, 2002 (suppl 9)
16. Miller KD, Picus J, Blanke C, et al: Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer. Ann Oncol 11:101-103, 2000
17. Adjei AA, Erlichman C, Sloan JA, et al: Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. J Clin Oncol 18:1748-1757, 2000
18. Kindler HL, Dugan W, Hochster H, et al: Clinical outcome in patients (pts) with advanced pancreatic cancer treated with pemetrexed/gemcitabine. Proc Am Soc Clin Oncol 21:A499, 2002 (abstr)
19. Rougier P, Ducreux M, Ould Kaci M, et al: Randomized phase II 11 study of oxaliplatin alone (OXA), 5-fluorouracil (5FU) alone, and the two drugs combined (OXA-FU) in advanced or metastatic pancreatic adenocarcinoma (APC). Proc Am Soc Clin Oncol 21:A1018, 2000 (abstr)
20. Louvet, C, André T, Lledo G, et al: Gemcitabine-oxaliplatin (GEMOX) combination in advanced pancreatic carcinoma (APC): A GERCOR multicenter phase II study. Proc Am Soc Clin Oncol 20:A506, 2001 (abstr)
21. Safran H, Ramanathan RK, Schwartz J, et al: Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Proc Am Soc Clin Oncol 20:A517, 2001 (abstr)
22. Abbruzzese JL, Rosenberg A, Xiong Q, et al: Phase II study of anti-epidermal growth factor receptor (EGFR) antibody cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol 20:A518, 2001 (abstr)
23. McGinn CJ, Zalupski MM, Shureiqi I, et al: A phase I trial of radiation dose escalation with concurrent weekly full dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 19:4202-4208, 2001